|
業務類別
|
Biotechnology |
|
業務概覽
|
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication. |
| 公司地址
| 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021 |
| 電話號碼
| +1 604 210-2217 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.achievelifesciences.com |
| 員工數量
| 28 |
| Dr. Cindy Jacobs,PhD,M.D. |
Director, President and Chief Medical Officer |
美元 484.67K |
11/09/2025 |
| Dr. Anthony Clarke,PhD |
Chief Scientific Officer |
-- |
21/04/2022 |
| Mr. John Bencich |
Director, Principal Financial Officer and Chief Executive Officer |
美元 530.00K |
26/04/2024 |
| Mr. Mark K. Oki |
Chief Financial Officer |
-- |
08/06/2026 |
| Mr. Jerry Wan |
Principal Accounting Officer and Vice President, Finance |
-- |
24/03/2026 |
| Dr. Andrew Goldberg, M.D. |
Chief Executive Officer, President and Director |
-- |
16/04/2026 |
| Mr. Erik Atkisson |
Chief Legal Officer |
美元 130.26K |
08/06/2026 |
| Mr. Benjamin Halladay |
Chief Financial Officer |
-- |
01/10/2026 |
| Ms. Jaime Xinos |
Chief Commercial Officer |
-- |
12/05/2026 |
| Mr. Craig Donnelly |
Chief Operations Officer |
-- |
08/06/2026 |
| Mr. Mark Lawrence Rubinstein |
Chief Medical Officer |
-- |
08/06/2026 |
| Mr. Ronald Dadino |
Senior Vice President, Chemistry, Manufacturing and Controls and Supply Chain |
-- |
03/08/2026 |
| Ms. Gloria Cosgrove |
Senior Vice President, Quality |
-- |
03/08/2026 |
|
|
| Dr. Cindy Jacobs,PhD,M.D. |
Director, President and Chief Medical Officer |
11/09/2025 |
| Mr. Donald R. Joseph |
Lead Independent Director |
30/03/2023 |
| Mr. Jeffrey S. Farrow |
Independent Director |
08/06/2026 |
| Dr. Martin A. Mattingly,Pharm.D. |
Independent Director |
30/03/2023 |
| Mr. Thomas Braxton King |
Interim Executive Chairman of the Board |
12/05/2026 |
| Mr. Jay M. Moyes |
Independent Director |
30/03/2023 |
| Dr. Vaughn B. Himes,PhD |
Independent Director |
26/04/2024 |
| Mr. John Bencich |
Director, Principal Financial Officer and Chief Executive Officer |
26/04/2024 |
| Mr. Richard Alistair Balfour Stewart |
Director |
16/04/2026 |
| Dr. Bridget A. Martell, M.D. |
Independent Director |
08/06/2026 |
| Dr. Aaron Royston, M.D. |
Independent Director |
12/05/2026 |
| Ms. Kristen B. Slaoui, PhD |
Director |
10/01/2025 |
| Dr. Andrew Goldberg, M.D. |
Chief Executive Officer, President and Director |
16/04/2026 |
| Dr. Lucian Iancovici, M.D. |
Chairman of the Board |
12/05/2026 |
| Mr. Thomas Sellig |
Independent Director |
08/06/2026 |
| Mr. Stuart M. Duty |
Independent Director |
08/06/2026 |
| Mr. Tom Sellig |
Director |
30/03/2023 |
| Ms. Nancy R. Phelan |
Independent Director |
08/06/2026 |
| Dr. Kristin Slaoui, PhD |
Independent Director |
08/06/2026 |
| Mr. Christopher Martin |
Director |
12/05/2026 |
| Mr. Jeffery Farrow |
Director |
02/06/2026 |
| Dr. Reid Waldman, M.D. |
Director |
02/06/2026 |
| Mr. Chris Martin |
Independent Director |
08/06/2026 |
|
|
|
|